Dr Mark Linch
Dr Mark Linch is a Honorary Consultant Medical Oncologist at University College London (UCL) Hospital and Associate Professor at the UCL Cancer Institute where he leads the Urological Cancer Biology Group. He specialises in the treatment of prostate and bladder cancers.
Bio
Dr Mark Linch is a Medical Oncologist specialising in the management of patients with prostate cancer and bladder cancer. He has a particular interest in tailoring immunotherapy, hormonal treatment and chemotherapy based on the molecular and clinical features of individual patients.
Dr Linch is an Associate Professor at University College London (UCL) Cancer Institute, Honorary Consultant Medical Oncologist and Director of Innovation at The London Clinic. Dr Linch trained in medical oncology at the Royal Marsden Hospital (RMH), London. In 2012 he was awarded a PhD in Cancer Cell Biology from UCL and the Cancer Research UK London Research Institute (LRI), now known as the Francis Crick Institute. He continued his post-doctoral studies at the LRI while also working as a Consultant Medical Oncologist at RMH. In 2014 Dr Linch moved to UCL to specialise in the clinical management and translational biology of prostate and bladder cancer.
His research is focused on the immune biology of these cancers with a view to identifying rational immunotherapy combinations, predictive biomarkers and novel liquid biopsy strategies. He is chief investigator of a number national and international combination immunotherapy trials in bladder and prostate cancer, leads the UCL CRUK Cancer Trial Centre Urology group, sits on the Prostate Cancer UK Clinical Advisory Group, and is an inaugural member of the UK Bladder Cancer Translational Group. This is funded by the NIHR/BRC, CRUK, Rosetrees Trust, Prostate Cancer Foundation, Prostate Cancer UK and philanthropic donations from Percy Stevens and Sir Peter Wood.
Areas of expertise
- Checkpoint inhibitors
- Antibody drug conjugates
- Bispecific T-cell engagers
- Radionuclide therapy
- Chemotherapy
- Tumour profiling
- Liquid biopsies
More information
142-146 Harley Street
London, W1G 7LD
- The Royal Marsden Hospital 2014
- University College London 2012
- Leeds University Medical School 2000
- Consultant Medical Oncologist
University College London Hospital - Director of Innovation
The London Clinic
- Associate Professor of Oncology
University College London
- Advanced therapeutics
- Chemotherapy
- Immunotherapy
- Medical Oncology
- Uro-oncology
- Leone G, … Linch M. Nivolumab and ipilimumab for metastatic castration-resistant prostate cancer with an immunogenic signature: the multicentre, two-cohort, phase 2 NEPTUNES study. J Clin Oncol Jul 2025.
- Dev H, Linch M, … Pacey S. Cambridge Neoadjuvant Cancer of the Prostate (CANCAP03): A Window Study into the Effects of Olaparib ± Degarelix in Primary Prostate Cancer. Clin Cancer Res. Jun 2025.
- Yu EY, Linch M,..de Bono JS. Pembrolizumab plus abiraterone acetate and prednisone in Patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results for KEYNOTE-365 Cohort D.
- Eur Urol Oncol. Jun 2025; 8(3):641-651.
- Craddock C,…Linch M,..Winter H. UK cancer vaccine advance – Recognising and realising opportunities. Camb Prism Precis Med. Jan 2025.
- Jones R, Crabb S, Linch M,..Hussain S. Systemic anticancer therapy for urothelial carcinoma: UK oncologists’ perspective. Br J Cancer 2024 Apr; 130(6):897-907.
- Hasan AM…., Linch M, … Attard G. Treatment-mediated selection of lethal prostate cancer clones defined by copy number architectures. Nat Commun. 2023 Aug 10;14(1):4823.
- Jones M, …. Linch M, McDonald NQ, Cryo-EM Structure of the XPF-ERCC1 Endonuclease Reveals an Auto-Inhibited Conformation. Nat Commun, 2020 Feb 28;11(1):1120.
- Powles T, …Linch M, …Castellano D. Predictors of outcome to neoadjuvant PD-L1 blockage in operable urothelial cancer. Nat Med. 2019, 25(11), 1706-1714.
- Linch, M.,… Swanton, .C. Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Ann Oncol 2017: 28(10), 2472-2480.
- Linch M, …Parker PJ. A cancer-associated mutation in atypical protein kinase C iota occurs in a substrate-specific recruitment motif. Science signaling 2013;6:ra82